West Nile screening
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe plans to submit a BLA for its WNV blood screening assay after the 2004 mosquito season, VP-Regulatory, Quality & Government Affairs Glen Freiberg reports during a Q3 earnings call Oct. 30. The firm will use the time to "cost-effectively manufacture...and collect the clinical data" from three validation lots required for the BLA, Freiberg explains. Both Gen-Probe and Roche obtained IND status for WNV screens in late May. Gen-Probe reported WNV assay sales of $1.4 mil. for the quarter, with pricing restricted to IND cost recovery levels. Meanwhile, CBER is examining 2003 mosquito season data to determine an appropriate WNV viremia standard for approval of screens, Division of Emerging & Transfusion Transmitted Diseases Director Hira Nakhasi, PhD, notes at a recent FDA bioterrorism seminar...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.